Get started
Author

Isac Ribeiro Moulaz

Observed names: I. Moulaz, I. Ribeiro Moulaz, Isac Moulaz, Isac R. Moulaz, Isac Ribeiro Moula, Moulaz, Isac Ribeiro
ORCID: 0000-0003-1014-9581
Observed ORCID: 0000-0003-1014-9581
OpenAlex ID: A5028991987
Pulmonary function evaluation after hospital discharge of patients with severe COVID-19
2021 · Jessica Polese, Larissa Sant'Ana, et al. · Clinics · 26
PDF
Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta‐analysis of randomized clinical trials
2024 · Milene Vitória Sampaio Sobral, João Lucas de Magalhães Leal Moreira, et al. · International Journal of Dermatology · 17
PDF
Prevalence of Sjögren's syndrome according to 2016 ACR-EULAR classification criteria in patients with systemic lupus erythematosus
2023 · Ana Paula Espíndula Gianordoli, Rafaella Vila Real Barbosa Laguardia, et al. · Revista Brasileira de Reumatologia · 16
PDF
Cross-sectional study of psychiatric disorders in patients with chronic musculoskeletal pain and individuals without pain
2024 · Ruben Horst Duque, Carla Vasconcelos Cáspar Andrade, et al. · Revista Brasileira de Reumatologia · 13
Pulmonary function and exercise capacity six months after hospital discharge of patients with severe COVID-19
2023 · Jessica Polese, Alessandro Demoner Ramos, et al. · The Brazilian Journal of Infectious Diseases · 12
Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project
2022 · Valéria Valim, Olindo Assis Martins-Filho, et al. · Frontiers in Immunology · 11
PDF
Cardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
2025 · Milene Vitória Sampaio Sobral, Livia Kneipp Rodrigues, et al. · American Journal of Cardiovascular Drugs · 7
Immunogenicity and Safety According to Immunosuppressive Drugs and Different COVID-19 Vaccine Platforms in Immune-Mediated Disease: Data from SAFER Cohort
2024 · Ketty Lysie Libardi Lira Machado, Ana Paula Neves Burian, et al. · Vaccines · 6
PDF
Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: data from the Brazilian multicentric study safer
2024 · Vitor Alves Cruz, Camila Guimarães, et al. · Revista Brasileira de Reumatologia · 6
PDF
Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose
2023 · Maria da Penha Gomes Gouvea, Ketty Lysie Libardi Lira Machado, et al. · Vaccine · 6
Antisynthetase Syndrome after chikungunya infection: A case report
2022 · Raiza Cansian Tuão, Mariana de Oliveira Macabú, et al. · Clinical Case Reports · 6
Adult-onset Still's disease after ChAdOx1 nCoV-19 vaccine: a possible association
2022 · Laíssa Fiorotti Albertino, Isac Ribeiro Moulaz, et al. · Autopsy and Case Reports · 4
PDF
Giant lactating adenoma
2021 · Isac Ribeiro Moulaz, Fernanda Sales Soares de Oliveira, et al. · Autopsy and Case Reports · 4
PDF
Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren’s syndrome
2024 · Ketty Lysie Libardi Lira Machado, Ismael Artur da Costa-Rocha, et al. · Human Vaccines & Immunotherapeutics · 3
Trombose Venosa Profunda Tardia Após Covid‐19: Relato De Caso
2021 · Gabriel Carnieli Silveira, Julia Muniz Bernardi, et al. · The Brazilian Journal of Infectious Diseases · 3
PDF
Leprosy mimicking autoimmune diseases: a case series
2023 · Danielle Busato Aride, Bárbara Ferraço Dalmaso, et al. · Clinical and Experimental Rheumatology · 2
Clinical risk factors for predicting anti-Sars-CoV-2 antibody immunoreactivity duration after mild COVID-19 infection
2023 · Maria Da Penha Gomes Gouvea, Allan Gonçalves Henriques, et al. · Journal of Human Growth and Development · 2
PDF
Eventos Adversos Às Vacinas Coronavac E Astrazeneca Em Uma Coorte De Trabalhadores Da Saúde
2022 · Maria da Penha Gomes Gouvea, Waltésia Perini Rocha, et al. · The Brazilian Journal of Infectious Diseases · 2
PDF
Third Booster Half Dose of ChAdOx1-nCov-19 Is Effective, Safe, and Induces Long-Duration Humoral and Cellular Immune Response to Omicron: 1-Year Follow-Up of Viana Study
2025 · Nésio Medeiros-Junior, Maria Gouvea, et al. · Vaccines · 1
PDF
Efficacy and Safety of Inhibitors of the Proximal Pathway of the Complement System in Paroxysmal Nocturnal Hemoglobinuria: A Meta-analysis of Randomized Controlled Trials
2024 · Milene Vitória Sampaio Sobral, Isac Ribeiro Moulaz, et al. · American Journal of Therapeutics · 1
Pos0271 Heterologous Covid-19 Booster Vaccination Produced Greater Antibody Titers in Autoimmune Disease Patients: Data From Multicentric Prospective Phase Iv Safer Study
2023 · K. Lysie Libardi Lira Machado, S. T. Miyamoto, et al. · Annals of the Rheumatic Diseases · 1
PDF
Reatividade Vacinal E Duração De Resposta Imune Da Coronavac E Astrazeneca Em Uma Coorte De Trabalhadores
2022 · Maria da Penha Gomes Gouvea, Isac Ribeiro Moula, et al. · The Brazilian Journal of Infectious Diseases · 1
PDF
Artrite fúngica por Exophiala em paciente com lúpus eritematoso sistêmico
2025 · Claudia Correa Ribeiro, Rodrigo Mazzini Calmon Alves, et al. · Revista Brasileira de Pesquisa em Saúde/Brazilian Journal of Health Research
PDF
Pos0572 Factors Associated With Vaccine Response After Covid Vaccine Booster in Patients With Autoimmune Diseases: Data From Multicentric Prospective Phase Iv Safer Study
2024 · K. Lysie Libardi Lira Machado, S.T. Miyamoto, et al. · Annals of the Rheumatic Diseases
Ab0078 Predictors of Hospitalization Due to Breakthrough Covid-19 Infection in Patients With Immune-mediated Rheumatic Diseases: Data From Safer Study
2024 · D. Calderaro, K. Lysie Libardi Lira Machado, et al. · Annals of the Rheumatic Diseases
Works count: 54
Citation count: 150
H-index: 7
I10-index: 6
Year
Topic
Type